TENX
TENAX THERAPEUTICS, INC.
$11.48
+6.99%
$304.5M
No data for this timeframe.
Vol
Market Cap$304.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders35 funds
Inst. Value$109.2M
Inst. Activity7 buys / 0 sells
SEC Reports5
Press Releases1
Recent Activity
May 12, 2026
SEC
Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, though net loss widened to $15.
8-K — Impact 4/10
May 12, 2026
SEC
Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, but net loss widened to $15.7M
PRESS-RELEASE — Impact 5/10
May 12, 2026
earnings
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>On track to report topline data from Phase 3 LEVEL study of TNX-103 in third q
May 11, 2026
Insider
STAAB THOMAS R II was granted 10,000 shares
Chief Financial Officer
May 11, 2026
Insider
STAAB THOMAS R II was granted 450,000 shares
Chief Financial Officer
Apr 22, 2026
SEC
Tenax Therapeutics filed its definitive proxy statement (DEFA14A) for its 2026 annual meeting, which includes the re-ele
DEFA14A — Impact 3/10
Jan 30, 2026
Insider
MCGAULEY THOMAS acquired via exercise 50,000 shares
Interim CFO
Inst.
JANUS HENDERSON GROUP PLC — DOUBLED
1,815,474 shares ($29.1M)
Price Targets
$34.00
+196.2% upside
Strong Buy
Current $11.48
Low $26.00
Median $34.00
High $50.00
7 analysts
$26.00
$50.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 12, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Mar 17, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Mar 16, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Dec 17, 2025 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.37 ▲ +6.3% | $-0.37 — $-0.37 | -37% YoY | 2 |
| Next Q | $-0.41 ▲ +4.7% | $-0.41 — $-0.40 | -1% YoY | 2 |
| Current FY | $-1.56 ▼ -3.6% | $-1.59 — $-1.54 | -17% YoY | 4 |
| Next FY | $-1.41 | $-1.56 — $-1.27 | 10% YoY | 5 |
Latest Reports
NEUTRAL
8-K
4/10
Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, though net loss widened to $15.
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, but net loss widened to $15.7M
May 12, 2026
MIXED
Press
6/10
Tenax Therapeutics reported financial results for 2025, highlighted by a significant increase in R&D and G&A expenses le
Mar 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| JANUS HENDERSON GROUP PLC | $29.1M | DOUBLED |
| MORGAN STANLEY | $9.5M | DOUBLED |
| ADAGE CAPITAL PARTNERS GP, | $8.6M | DOUBLED |
| Point72 Asset Management, L.P. | $8.5M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | STAAB THOMAS | A | $0.00 |
| May 11, 2026 | STAAB THOMAS | A | $0.00 |
| Jan 30, 2026 | MCGAULEY THOMAS | M | $0.00 |
35 institutional holders with $109.2M total value (9,819,109 shares) as of 2026-Q1. Top holders: ROYAL, JANUS, MORGAN. Net buying activity: 7 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 4 | $0.00 | 0.0% | — |
| 2 | JANUS HENDERSON GROUP PLC | 1,815,474 | $29.1M | 26.6% | DOUBLED +989.3% |
| 3 | MORGAN STANLEY | 596,564 | $9.5M | 8.7% | DOUBLED +234.4% |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 540,126 | $8.6M | 7.9% | DOUBLED +548.2% |
| 5 | Point72 Asset Management, L.P. | 533,965 | $8.5M | 7.8% | ADD +26.1% |
| 6 | TD ASSET MANAGEMENT INC | 399,184 | $6.4M | 5.8% | — |
| 7 | RTW INVESTMENTS, LP | 370,246 | $5.9M | 5.4% | — |
| 8 | MARSHALL WACE, LLP | 352,572 | $5.6M | 5.2% | ADD +68.2% |
| 9 | Woodline Partners LP | 323,911 | $5.2M | 4.7% | DOUBLED +125.8% |
| 10 | FMR LLC | 322,600 | $5.2M | 4.7% | DOUBLED +128.6% |
| 11 | AMERIPRISE FINANCIAL INC | 279,537 | $4.5M | 4.1% | — |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 263,421 | $4.2M | 3.9% | — |
| 13 | BALYASNY ASSET MANAGEMENT L.P. | 194,616 | $3.1M | 2.8% | — |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 152,600 | $2.4M | 2.2% | DOUBLED +121.9% |
| 15 | CITADEL ADVISORS LLC | 152,516 | $2.4M | 2.2% | DOUBLED +318.1% |
| 16 | ExodusPoint Capital Management, LP | 120,529 | $1.9M | 1.8% | — |
| 17 | TWO SIGMA INVESTMENTS, LP | 68,588 | $1.1M | 1.0% | — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 62,786 | $1.0M | 0.9% | — |
| 19 | Trexquant Investment LP | 50,712 | $810.9K | 0.7% | — |
| 20 | VANGUARD FIDUCIARY TRUST CO | 33,430 | $534.5K | 0.5% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | DOUBLED | 166,666 | 1,815,474 | +989.3% | $29.1M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 83,333 | 540,126 | +548.2% | $8.6M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 423,415 | 533,965 | +26.1% | $8.5M | 2026-Q1 |
| Woodline Partners LP | DOUBLED | 143,481 | 323,911 | +125.8% | $5.2M | 2026-Q1 |
| FMR LLC | DOUBLED | 141,100 | 322,600 | +128.6% | $5.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 3,780 | 18,569 | +391.2% | $296.9K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 1 | 2,501 | +250000.0% | $40.0K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 178,329 | 596,376 | +234.4% | $7.3M | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 177,209 | 298,153 | +68.2% | $3.6M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 161,800 | 255,664 | +58.0% | $3.1M | 2025-Q4 |
| Woodline Partners LP | ADD | 88,211 | 143,481 | +62.7% | $1.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 56,600 | 125,579 | +121.9% | $1.5M | 2025-Q4 |
| BlackRock, Inc. | DOUBLED | 301 | 16,714 | +5452.8% | $203.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 254 | 3,780 | +1388.2% | $46.1K | 2025-Q4 |
| Rockefeller Capital Management L.P. | TRIM | 2 | 1 | -50.0% | $12.00 | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 22,287 | 161,800 | +626.0% | $1.2M | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 10,345 | 43,253 | +318.1% | $329.2K | 2025-Q3 |
| UBS Group AG | DOUBLED | 14 | 119 | +750.0% | $906.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 2,893 | 14 | -99.5% | $81.00 | 2025-Q2 |
| MORGAN STANLEY | ADD | 74,445 | 121,094 | +62.7% | $793.2K | 2025-Q1 |
| UBS Group AG | DOUBLED | 3 | 2,893 | +96333.3% | $18.9K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 28 | 229 | +717.9% | $1.5K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 260 | 74,445 | +28532.7% | $460.8K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 688 | 3 | -99.6% | $18.00 | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 16 | 28 | +75.0% | $97.00 | 2024-Q3 |
2 unique insiders with 3 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | STAAB THOMAS R II | Chief Financial Officer | AWARD | 10,000 | — | — |
| May 11, 2026 | STAAB THOMAS R II | Chief Financial Officer | AWARD | 450,000 | — | — |
| Jan 30, 2026 | MCGAULEY THOMAS | Interim CFO | EXERCISE | 50,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.8/10.
NEUTRAL
8-K
4/10
Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, though net
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, but net los
May 12, 2026
NEUTRAL
DEFA14A
3/10
Tenax Therapeutics filed its definitive proxy statement (DEFA14A) for its 2026 annual meeting, which
Apr 22, 2026
NEUTRAL
8-K
3/10
Tenax Therapeutics appointed Thomas R. Staab, II as Chief Financial Officer effective May 11, 2026,
Apr 22, 2026
NEUTRAL
S-3
4/10
Tenax Therapeutics has filed a shelf registration (S-3) to raise up to $300 million through future o
Mar 24, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$34.00 mean target
+196.2% upside
Strong Buy (1.14)
$26.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $11.48 |
| Target Low | $26.00 |
| Target Mean | $34.00 |
| Target Median | $34.00 |
| Target High | $50.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.37 | $-0.37 | $-0.37 | -37.0% | +6.3% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.41 | $-0.41 | $-0.40 | -1.3% | +4.7% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.56 | $-1.59 | $-1.54 | -16.6% | -3.6% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-1.41 | $-1.56 | $-1.27 | 9.8% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.370 | |
| 7d ago | $-0.370 | |
| 30d ago | $-0.395 | +0.025 |
| 60d ago | $-0.410 | +0.040 |
| 90d ago | $-0.410 | +0.040 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 12, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 17, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Mar 16, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026</em></p>
May 12, 2026
earnings_calendar
TENX Q1 2026 Earnings Scheduled — 2026-05-12
May 8, 2026
contract
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a
May 4, 2026
other
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience <pre>Mr. Healey is a seaso
Apr 22, 2026
Clinical Trial
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Phase Phase 2 — COMPLETED
Apr 22, 2026
other
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
<p align="center"><em>Mr. Staab has over 25 years of financial and executive experience across the healthcare industry</em><br></p>
Apr 10, 2026
short_interest
FTD: TENX — 40,470 shares ($0.6M) failed to deliver
Settlement: 20260410, Price: $14.96, FTD Value: $605,431.2, TENAX THERAPEUTICS INC COM PAR
Mar 23, 2026
earnings_calendar
TENX Q4 2025 Earnings After Market Close — 2026-03-23
Mar 10, 2026
earnings
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
<p align="center"><em>Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026</em></p>
Feb 9, 2026
short_interest
FTD: TENX — 74,000 shares ($0.9M) failed to deliver
Settlement: 20260209, Price: $12.73, FTD Value: $942,020, TENAX THERAPEUTICS INC COM PAR
Feb 6, 2026
short_interest
FTD: TENX — 88,800 shares ($1.1M) failed to deliver
Settlement: 20260206, Price: $12.36, FTD Value: $1,097,568, TENAX THERAPEUTICS INC COM PAR
Feb 5, 2026
short_interest
FTD: TENX — 88,800 shares ($1.2M) failed to deliver
Settlement: 20260205, Price: $13.13, FTD Value: $1,165,944, TENAX THERAPEUTICS INC COM PAR
Feb 4, 2026
short_interest
FTD: TENX — 89,702 shares ($1.2M) failed to deliver
Settlement: 20260204, Price: $12.95, FTD Value: $1,161,640.9, TENAX THERAPEUTICS INC COM PAR
Feb 3, 2026
short_interest
FTD: TENX — 88,800 shares ($1.1M) failed to deliver
Settlement: 20260203, Price: $12.95, FTD Value: $1,149,960, TENAX THERAPEUTICS INC COM PAR
Feb 2, 2026
short_interest
FTD: TENX — 44,087 shares ($0.6M) failed to deliver
Settlement: 20260202, Price: $12.51, FTD Value: $551,528.37, TENAX THERAPEUTICS INC COM PAR